Cardiovascular Health Education Via Virtual Reality for Breast Cancer Survivors Receiving Anthracyclines or Trastuzumab
2 other identifiers
interventional
30
1 country
3
Brief Summary
The main goal of this study is to test a virtual reality (VR) program, Survivors' Virtual Reality Survivorship Experience (SurviVRSE), designed to help Breast Cancer survivors (n=30) learn about heart health. The aims are to test the usability, feasibility, and acceptability o the intervention. Additionally, follow-up assessments will examine changes in women's cancer therapy related cardiac dysfunction knowledge and heart healthy behaviors (e.g., physical activity).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable breast-cancer
Started May 2026
Shorter than P25 for not_applicable breast-cancer
3 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
February 16, 2026
CompletedFirst Posted
Study publicly available on registry
February 23, 2026
CompletedStudy Start
First participant enrolled
May 20, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 30, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
February 28, 2027
June 10, 2026
June 1, 2026
2 months
February 16, 2026
June 9, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (4)
CTRCD Knowledge
Change in knowledge of CTRCD and in measures of improving cardiovascular health. This investigator-developed true/false knowledge survey consists of 10 items that directly assess knowledge learned in SurviVRSE. Scoring this scale will consist of summing up the total items that were answered correctly (range = 0-10; 0 = no knowledge and 10=high knowledge).
Baseline, within 2 days post-Intervention, and 4 weeks post-intervention
Usability
Usability will be assessed using the Virtual Reality System Usability Questionnaire. This 10-item measure includes prompts such as "I think I would like to use this system frequently" and "I thought the system was easy to use." Women will respond to the items using a 5-point Likert scale (1= strongly disagree and 5= strongly agree). Scores will be totaled (with some items requiring reverse-coding).
Within 2 days post-Intervention
Acceptability
Acceptability will be assessed using the User Experience Questionnaire, a validated 8-item 7-point Likert scale survey that measures pragmatic and hedonic qualities of SurviVRSE (e.g., obstructive/supportive, complicated/easy). The UEC developers provide an Excel spreadsheet to analyze data collected from the tool. https://www.ueq-online.org/. The range of the scales is between -3 (horribly bad) to +3 (extremely good).
Within 2 days post-Intervention
User Satisfaction
SurviVRSE satisfaction and engagement will be assessed using an adapted 6-item 5-point Likert scale survey (1=strongly disagree and 5=strongly agree). Items include "I could engage SurviVRSE," I would recommend SurviVRSE to another survivor," and "I liked the music." To evaluate satisfaction, the six items will be totaled. Scores will range from 6-30 with higher scores indicating greater satisfaction.
Within 2 days post-Intervention
Secondary Outcomes (4)
Physical Activity
Baseline and 4 weeks post-intervention
Sleep Quality
Baseline and 4 weeks post-intervention
Tobacco Use
Baseline and 4 weeks post-intervention
Intent to Change Behavior
Baseline, within 2 days post-Intervention, and 4 weeks post-intervention
Study Arms (1)
Virtual Reality Group
EXPERIMENTALIndividuals in this arm will receive access to the virtual reality in cardiovascular health education and gaming intervention
Interventions
Prior to engaging the intervention, participants will complete a baseline survey. The virtual reality intervention will be delivered at one infusion treatment. Participants will complete all education modules and affiliated games. The education focuses on potentially cardiotoxic treatments (e.g., anthracyclines), ways to identify cancer treatment related cardiovascular dysfunction, and heart healthy behaviors that survivors can initiate during survivorship. Following the intervention participants will complete a survey similar to the baseline survey. One-month following the intervention participants will complete one final survey.
Eligibility Criteria
You may qualify if:
- years of age or older
- Able to speak and read in English
- Actively receiving Trastuzumab or an anthracycline-based treatment
- Currently receiving immunotherapy. This includes pembrolizumab and atezolizumab.
- Diagnosed with stages 0-III Breast Cancer
You may not qualify if:
- \- History of prior Breast Cancer diagnosis (i.e., not their first breast cancer diagnosis)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (3)
Adult Outpatient Pavilion
Richmond, Virginia, 23220, United States
Cellular Immunotherapies and Transplant Department
Richmond, Virginia, 23220, United States
VCU Health at Stony Point
Richmond, Virginia, 23223, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Arnethea Sutton, Ph.D
Virginia Commonwealth University
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- SUPPORTIVE CARE
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
February 16, 2026
First Posted
February 23, 2026
Study Start
May 20, 2026
Primary Completion (Estimated)
July 30, 2026
Study Completion (Estimated)
February 28, 2027
Last Updated
June 10, 2026
Record last verified: 2026-06
Data Sharing
- IPD Sharing
- Will not share